ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

Q&A

Q&A

Anca D. Askanase, M.D., MPH

LFA-REAL offers a straight-forward evaluation for lupus-affected organ systems, a study shows.

Richard Alan Furie, M.D.

Anifrolumab, a type 1 interferon receptor antagonist, performs well in early trial, researchers show.

Sharon Kolasinski, M.D.

Patients sometimes insist on non-traditional therapies after a rheumatoid arthritis diagnosis. Their concerns shouldn't be ignored and instead, patients should be counseled on therapeutic options.

Marcy B.Bolster, M.D.

Facing a growing shortage, rheumatology is looking to attract the next generation of providers.

Jonathan S. Hausmann, M.D.

Retaining international medical students, addressing student loan debt, mentoring and case-based teaching could possibly reverse the rheumatologist shortage, analysis says.

Felipe Andrade, M.D., Ph.D.

In this Q&A we feature a conversation with Felipe Andrade, M.D., Ph.D., of the Johns Hopkins University School of Medicine in Baltimore.

©bleakstar/Shuttersstock.com

The 2015 recommendations for PsA treatment highlight the importance of managing comorbidities and a patient-centered treatment approach.

Pages

Subscribe to Q&A on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.